Incyte CORP 10-Q quarterly reports

Incyte Corporation announced significant revenue growth and net income for the second quarter and first half of 2026, driven by strong performance across its hematology and oncology franchises, particularly JAKAFI and OPZELURA.

Incyte Corporation announced robust financial results for the first quarter of 2026, with total revenues reaching $1.27 billion, a significant increase driven by strong net sales across its product portfolio, particularly JAKAFI and OPZELURA.

Incyte Corporation delivered robust financial results for Q3 2025, driven by strong product sales and a favorable resolution of a key royalty dispute, significantly boosting net income.

Incyte Corporation achieved significant net income in the second quarter of 2025, driven by robust product revenue increases across its oncology and dermatology portfolios and strategic advancements in its clinical pipeline.

Incyte Corporation announces positive first quarter 2025 financial results, highlighted by increased product revenues and strategic advancements in its pipeline.

Incyte's Q3 2024 results show a net income of $106.5 million, a decrease compared to the previous year, alongside significant strategic moves including a pipeline review and acquisition integration.

Incyte Corporation's Q2 2024 results show a net loss primarily due to acquisition-related expenses and a significant share repurchase program, despite increased product revenues.

Incyte Corporation reported a significant increase in net income for the first quarter of 2024, driven by strong product revenue growth and strategic acquisitions.